Macrophage-Targeted Lysins Evade TB Persistence

[THEO] Okay, picture this: You’ve got a really stubborn infection. We’re talking about Mycobacterium tuberculosis, the bacteria behind TB. It’s notorious for hiding inside our own immune cells, specifically macrophages, making it super hard for drugs to reach. It’s like a tiny, bacterial submarine tucked away inside your body’s own defense system.

[DR. MARA] Indeed. *M. tuberculosis* thrives precisely because it can persist within alveolar macrophages, evading many conventional antibiotics. Reaching these intracellular pathogens is a significant hurdle in TB treatment.

[THEO] Right. So, how do you get your medicine *inside* that macrophage, directly to the bacterial hideout, without harming the macrophage itself? That’s the elegant problem Qiqi Wu and colleagues tackled in *Science Advances* this year. They used something called an extracellular contractile injection system – an eCIS.

[DR. MARA] An eCIS is essentially a molecular syringe. Think of it as a naturally occurring, self-assembling protein complex that bacteria like *Photorhabdus* use to inject toxins into target cells. It's built from a sheath, a tube, and crucially, a tail fiber that recognizes the target.

[THEO] And this tail fiber is the key to their genius, right? They didn't just use any old eCIS. They took one from *Photorhabdus*, called the PVC, or *Photorhabdus* virulence cassette. And then, they got really clever.

[DR. MARA] Precisely. The researchers re-engineered the PVC tail fiber. Instead of its natural target, they modified it to recognize CD11b. CD11b is a protein found on the surface of alveolar macrophages – those very cells where *M. tuberculosis* likes to reside.

[THEO] So, they’re basically putting a new address label on their molecular syringe, telling it, "Deliver here: macrophage, specifically the CD11b receptor." And what did they load into this tiny syringe?

[DR. MARA] They packaged a pair of mycobacteriophage-derived lysins, LysA and LysB, into the eCIS. Lysins are enzymes that specifically degrade bacterial cell walls. Phages, viruses that infect bacteria, often use them to break out of their host cells.

[THEO] So these lysins are like molecular crowbars, designed to smash open the *M. tuberculosis* cell wall. And the delivery system is specifically targeting the macrophage. How did they get this precise little package into the lungs where the infection is?

[DR. MARA] They delivered it via aerosol inhalation. The mice in their study inhaled the engineered eCIS loaded with lysins. This allowed the system to reach the pulmonary macrophages directly.

[THEO] And the results? Did their macrophage-targeting, lysin-loaded, aerosolized molecular syringe work?

[DR. MARA] Yes. The treatment led to a greater than 10-fold reduction in pulmonary *M. tuberculosis* H37Rv load in the infected mice. This indicates a very effective, localized delivery and action of the lysins against intracellular bacteria.

[THEO] A 10-fold reduction from a single intervention, delivered via inhalation. That’s pretty significant, especially for something as notoriously tough as TB inside macrophages.

[DR. MARA] It is. This approach offers a way to bypass host cell membranes and deliver antimicrobial cargo directly to intracellular pathogens with high specificity, which is a major challenge in infectious disease therapy.

[THEO] So, not only did they hit the target, but they hit it hard and specifically. This feels like it could be a game-changer for drug delivery, especially for those hard-to-reach intracellular infections, beyond just TB. You could, in theory, swap out that tail fiber for other targets, or the lysins for other therapeutic proteins.

[DR. MARA] The modularity of the eCIS system, particularly the engineered tail fiber, certainly suggests broader applications. It provides a robust platform for targeted intracellular delivery of various biomolecules.